@misc{Krochmalczyk_Dorota_Treatment_2010,
 author={Krochmalczyk, Dorota},
 address={Kraków},
 howpublished={online},
 year={2010},
 school={Wydział Lekarski},
 language={pol},
 abstract={Hodgkin’s lymphoma is a neoplastic disease with a relatively good prognosis, but at least 20% of patients are treated inappropriately. Study group consisted of 199 patients diagnosed with HL treated in the Hematology Clinic in Krakow. The study was designed to: 1. Assess the results of ABVD and BEACOPP escalated therapy 2. Analyze of the impact of 19 independent factors on survival 3. Compare of early toxicity of escalated chemotherapy and ABVD 4. Determine the effects of age, gender, risk group at diagnosis, and clinical stage on the toxicity 5. Assess the relationship between the conditions of treatment and the occurrence of infections Conclusions: 1. Ten-year OS in low-risk and intermediate risk group was 100%. In high-risk group ABVD therapy was less effective-OS: 82% versus escalated treatment group-OS: 95%. 2. Impact on survival in the whole group that had: type of first line treatment, the presence of CD20 antigen on the surface of RS cells, good early response to treatment. In the high-risk group treated with escalated BEACOPP regimen only few factors maintained prognostic significance: the early response to treatment and factors associated with tumor histology, such as histological subtype and the presence of CD20. 3. Early toxicity of BEACOPP escalated chemotherapy was statistically significantly higher than ABVD. 4. Age and gender had no},
 abstract={influence on toxicity. Clinical stage affected occurrence of side effects. 5. Patients treated with an outpatient basis had fewer and less severe infections than patients treated in the hospital.},
 title={Treatment escalation in Hodgkin’s lymphoma patients due to clinical and biological risk factors},
 type={Praca doktorska},
 keywords={Hodgkin’s lymphoma. chemioterapy eskBEACOPP, PET},
}